Biotech · Public company · Cambridge, MA, US

Intellia Therapeutics, Inc.

Ticker NTLA · SEC CIK 0001652130

Track this companyFree. Adds Intellia Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials43 recruiting or active

Pipeline programs4From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline4

NTLA-2001Phase 3 · Transthyretin Amyloidosis (ATTR) With CardiomyopathyClinicalTrials.gov · fetched Nov 12, 2026
NTLA-2002Phase 3 · Hereditary AngioedemaClinicalTrials.gov · fetched Nov 12, 2026
Arm 1: NTLA-5001Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Arm 2: NTLA-5001Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)PHASE3 · ACTIVE_NOT_RECRUITING · started Jan 15, 2025ClinicalTrials.gov NCT06634420 · fetched Nov 12, 2026
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia BPHASE1_PHASE2 · RECRUITING · started Sep 11, 2024ClinicalTrials.gov NCT06379789 · fetched Nov 12, 2026
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)PHASE3 · RECRUITING · started Dec 13, 2023ClinicalTrials.gov NCT06128629 · fetched Nov 12, 2026
Study Investigating NTLA-5001 in Subjects With Acute Myeloid LeukemiaPHASE1_PHASE2 · TERMINATED · started Dec 17, 2021ClinicalTrials.gov NCT05066165 · fetched Nov 12, 2026